Sofinnova Partners
Sofinnova Partners is an independent venture capital firm headquartered in Paris, France, with a focus on the life sciences sector. Established in 1972, the firm has financed nearly 500 companies over its 45-year history, primarily investing in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations. Sofinnova Partners actively sources investment opportunities, often taking the lead as the first institutional investor in Series A financings. The firm plays a significant role in guiding its portfolio companies, participating on their boards, and supporting them from the formation phase through to exit. While its primary investment focus is in Europe, the firm also makes select investments globally, concentrating on healthcare and sustainability sectors within life sciences, including biopharmaceuticals, biotech, medical devices, and industrial biotechnology.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
Zyl is a mobile application designed to help users gather and share memories with friends and family. Launched in 2015 and based in Saint-Maur-des-Fossés, France, Zyl enables users to discover meaningful moments from their photo libraries and share these memories through events created within the app. Users can invite friends to participate in these events, view a shared timeline, and synchronize photos related to those moments. The app addresses the common dilemma of photo sharing, where only a small fraction of memories are shared due to concerns about privacy and social validation. By focusing on fostering genuine connections, Zyl provides a platform for users to relive and share their experiences, promoting interaction and engagement with loved ones. The company, formerly known as Comet, rebranded to Zyl in November 2017.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.